Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

20021,164 citationsJournal Article

Authors

Thomas E. Witzig · Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Leo I. Gordon · Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Fernando Cabanillas · Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Myron S. Czuczman · Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Christos Emmanouilides · Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Robin Joyce · Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Abstract

Radioimmunotherapy with (90)Y ibritumomab tiuxetan is well tolerated and produces statistically and clinically significant higher ORR and CR compared with rituximab alone.

Topics & Keywords

Lymphoma Diagnosis and Treatment Cancer Immunotherapy and Biomarkers CAR-T cell therapy research

Publication Details

Published in: Journal of Clinical Oncology

Volume 20, Issue 10, pp. 2453-2463

DOI: 10.1200/jco.2002.11.076

Field-Weighted Citation Impact: 51.40

Command Palette

Randomized Controlled Trial of Yttrium-90–Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin’s Lymphoma

Authors

Abstract

Topics & Keywords

Publication Details